KH Neochem Co., Ltd. Overview
KH Neochem is a mid-cap Japanese specialty chemicals company built around one core process, oxo synthesis. In this process, olefins such as propylene react with "oxo gas," a mixture of carbon monoxide and hydrogen, to produce aldehydes. The aldehydes are then converted into alcohols and carboxylic acids. On this platform the company has built three positions.
Functional Materials: It claims the world's No.1 position in raw materials for refrigeration oil (isononanoic acid and 2-ethylhexanoic acid). These feed the synthetic polyol ester lubricants used in air conditioners that run on low global-warming-potential (GWP) refrigerants.
Electronic Materials: It is a leading supplier of ultra-high-purity PGME/PGMEA solvents used in photoresists, which ties it to AI-driven semiconductor demand.
Basic Chemicals: It is Japan's leading oxo-alcohol producer. This business is under structural pressure from Chinese overcapacity.
Functional and Electronic Materials produced about 93% of FY2025 business-field operating income on about 60% of sales. The company combines a 53.6% equity ratio, high free cash flow and an increasingly shareholder-focused capital policy. In August 2026 it raised its payout target to 50% and its dividend-on-equity (DOE) floor to 5%. This came while activist Strategic Capital held about 18% of the shares.
Company's own description
The FY2025 Annual Securities Report describes the group as consisting of the company, four subsidiaries and one affiliate. Its principal business is manufacturing and selling petrochemical products, using "oxo technology" as its core technology to supply distinctive chemical products to a wide range of industries.
The company began mass-producing aldehydes by the oxo process in 1970. Since then it has extended its product range downstream into alcohols and fatty acids, which supply solvents, plasticizer raw materials and functional materials to customers in Japan and abroad. The company reports a single segment, the "Chemicals Business." It discloses sales and operating income by three business fields:
-
Functional Materials
-
Electronic Materials
-
Basic Chemicals
[ASR FY2025, Section 1.3]
The corporate mission is to "realize a better tomorrow through the power of chemistry." VISION 2030 aims for the company to become "a specialty chemical company that shines globally." [ASR FY2025]
Independent characterization
KH Neochem is a mid-stream, process-integrated chemical converter. It buys naphtha-cracker derivatives, chiefly propylene and ethylene, from neighbouring cracker operators in the Yokkaichi (Mie) and Chiba (Ichihara) industrial complexes. It also buys LNG for energy and CO2 for oxo gas. It converts these through oxo, hydrogenation, oxidation and esterification steps into roughly three tiers of product.
-
Commodity oxo alcohols and solvents (Basic Chemicals). Examples are n-butanol, 2-ethylhexanol ("octanol"), isononyl alcohol ("Oxocol 900") and butyl acetate. These sell into plasticizers (DOP and DINP), acrylates, coatings and inks. Margins move with naphtha and Asian spreads and have compressed sharply as Chinese oxo capacity has come online. The FY2025 business-field operating margin was 2.0%.
-
Specialty acids and diols (Functional Materials). The key products are isononanoic acid (brand "Kyowanoic-N"), octylic acid (2-ethylhexanoic acid) and cosmetic-grade 1,3-butylene glycol. These are niche, technically demanding molecules with few global producers, sold under long qualification cycles to refrigeration-oil makers and cosmetics formulators. The FY2025 margin was 19.3%.
-
Ultra-high-purity electronic solvents (Electronic Materials). These are PM-P (PGME) and PMA-P (PGMEA) with metal content controlled at parts-per-trillion levels. In addition, subsidiary Kurokin Kasei does contract manufacturing of advanced semiconductor materials. The FY2025 margin was 21.8%.
Revenue model. The company earns essentially 100% product revenue from batch and continuous chemical sales. There is no meaningful service, subscription or licensing revenue. The one historical exception was technology-licensing income of about JPY 1.0 billion booked in 2016 from the aborted Taiwan joint venture. Revenue is recognized on delivery in Japan or on Incoterms risk transfer for exports. Certain toll-processing arrangements are recognized net, as are agent sales. [ASR FY2025, revenue recognition note]
Value-chain position. The company is downstream of crackers and refiners. Its customers include:
-
Idemitsu Kosan, its largest customer at 17.5% of FY2025 sales. Analyst inference: this is consistent with Idemitsu's position as a major refrigeration-oil formulator.
-
Miyako Chemical, a trading house and former affiliate sold to Chori in 2015, at 9.9% of sales.
-
Photoresist makers, including cross-shareholder Tokyo Ohka Kogyo.
-
Plasticizer makers, including its own J-Plus joint venture.
-
Paint companies such as Kansai Paint, and cosmetics manufacturers.
[ASR FY2025]
End markets.
-
Air conditioners and refrigeration
-
Semiconductors and flat-panel displays
-
Automotive (coatings, laminated-glass interlayers, wire coatings)
-
Housing and construction (wallpaper, flooring)
-
Cosmetics and personal care
-
Pharmaceuticals and agrochemical intermediates
Customer types. All customers are business-to-business industrial buyers. Japan accounted for 76.0% of FY2025 sales by customer location, China 11.2%, other Asia 6.8% and the rest of the world 6.0% (derived from [ASR FY2025] segment note). A large share of domestic sales are ultimately exported. For example, refrigeration-oil raw materials sold to Japanese lubricant formulators end up in Chinese and Indian air-conditioner compressors.
Sales mix by business field, FY2025 (JPY million)
Source: [ASR FY2025, MD&A]. Business-field operating income excludes company-wide administrative costs, which are shown as "Corporate costs."
Strategy
Stated strategy
VISION 2030, "A specialty chemical company that shines globally," has three aims [ASR FY2025]:
-
Supply specialty chemical materials that help curb global warming and support better lives.
-
Expand world-share-No.1 products and new businesses in the strategic domains of Environment, Healthcare and Electronics.
-
Achieve top-class operating margins among domestic chemical companies.
The original VISION 2030 numbers were sales of JPY 180 billion, operating income above JPY 25 billion, an operating margin of 15%, and ROE above 12% [V2030]. The 2018 materials also set an aspiration of 75% global share in refrigeration-oil raw materials by 2030.
5th MTP (2025–2027), "Toward a New Growth Stage" [MTP5; ASR FY2025]:
Strategy I: Strengthen earning power: - Functional Materials: use the "world No.1" capacity and global logistics network for refrigeration-oil raw materials; source competitive raw materials; raise productivity; expand sales of high-quality cosmetics raw materials, including inbound-tourism demand and overseas distribution.
-
Electronic Materials: expand sales to the leading-edge semiconductor segment and add value through quality.
-
Basic Chemicals: rationalize production and logistics, work with raw-material suppliers, and apply appropriate pricing. The FY2025 report adds "accelerate structural reform."
-
Target: the functional chemicals share of cumulative EBITDA rises from 77% (4th MTP) to 82%.
Strategy II: Lay the groundwork for the future: Move new products from "exploration" to "creation" (PHB, glycans, alicyclic optical monomers). Achieve the 2030 GHG target (-30% versus FY2017) early, during the MTP.
Strategy III: Strengthen the management foundation: Build plant capability (smart safety, predictive diagnostics, advanced process control); pursue DX (an in-house generative AI environment); invest in human capital (job-based HR system, selective leadership development, mid-career hiring, an HR business-partner role in plants from 2025).
Medium-term financial targets
| Metric | FY2024 actual | FY2025 actual | FY2027 target |
|---|---|---|---|
| Operating income (JPY bn) | 12.2 | 11.2 | 16.5 |
| EBITDA (JPY bn) | 17.2 | 17.6 | 23.6 |
| ROE (%) | 13 | 11 | 15 |
| ROIC (%) | 10 | 10 | 12 |
| EBITDA margin (%) | 14 | 15 | 18 |
| EBITDA per employee (JPY M) | 21 | 20 | 28 |
| Metric | Target |
|---|---|
| Operating income | JPY 44.9 billion |
| EBITDA | JPY 65.3 billion |
| Functional Materials EBITDA | JPY 48.9 billion |
| Electronic Materials EBITDA | JPY 11.1 billion |
| Basic Chemicals EBITDA | JPY 12.9 billion. This is shown as 13.6 in one version of the MTP pages, a source discrepancy. |
Cumulative 2025–2027 targets:
Source: [MTP5]; [ASR FY2025] KPI table.
The FY2027 operating income target is given as JPY 16.5 billion in [ASR FY2025] and [MTP5] page 35. One third-party summary of [MTP5] cites JPY 20.5 billion; that figure is inconsistent with the EBITDA target of JPY 23.6 billion, so JPY 16.5 billion is used here.
Progress check (derived). FY2025 operating income (JPY 11.2 billion) plus FY2026 guidance (JPY 13.5 billion) totals JPY 24.7 billion. Reaching the cumulative JPY 44.9 billion would require JPY 20.2 billion in FY2027. That is about 22% above the FY2027 single-year target. The cumulative target is very likely to be missed unless FY2026 materially beats guidance.
Capital allocation (5th MTP)
| Use | JPY Bn |
|---|---|
| Operating cash flow source (cumulative 2025–2027) | 48.0 |
| Growth and foundation investment (R&D, DX, maintenance and renewal) | 18.0 |
| Strategic investment window (M&A, restructuring, additional returns) | 13.5 |
| Shareholder returns | 16.5 |
Source: [MTP5].
Initiatives announced in the last 24 months (October 2024 – October 2026)
| Date | Initiative | Detail |
|---|---|---|
| Dec 2024 | Capital and business alliance with Beneino Technologies | Glycan-enhanced disulfide-rich peptide (DRP) drug discovery [ASR FY2024] |
| 7 Feb 2025 | 5th MTP launch | Targets as above; payout raised to 40%; DOE at least 4% |
| 7 Feb 2025 | Share buyback | Up to 2.5 million shares / JPY 5.0 billion; completed by September 2025 |
| Feb 2025 | Chiba CO2 recovery unit commissioned | Reduces CO2 procurement risk and Scope 1 emissions |
| 2,025 | HR business partners placed in plants; job-based HR extended | [ASR FY2025] |
| 2,025 | In-house generative AI rolled out with a training program | [ASR FY2025] |
| 2,025 | Chiba Plant obtains new certification under the High Pressure Gas Safety Act | Yokkaichi was certified in 2024 [ASR FY2025] |
| From 2024 | Internal carbon price of JPY 10,000 per tonne of CO2 | Applied to investment decisions |
| 2,026 | Basic Chemicals structural reform accelerated | [ASR FY2025]. Specific measures such as capacity closures or partnerships had not been disclosed as of October 2026. |
| Aug 2026 | Planned construction of a new Yokkaichi power-generation facility (JPY 350 million) | August 2026 to April 2028 |
| 4 Aug 2026 | Dividend policy upgrade | Payout about 50% (from 40%); DOE at least 5% (from 4%); applies from FY2026 [DIV 0804] |
| 11 May 2026 | Additional Board Benefit Trust contribution | Executive equity incentive |
Products & Services
Pricing models for the products below are not publicly disclosed. The company states that it passes raw-material and fuel cost changes into selling prices "in a timely and appropriate manner" [ASR FY2025]. Analyst inference: this is consistent with naphtha-linked formula pricing for Basic Chemicals and negotiated contract pricing for specialties.
Functional Materials
| Product / brand | Chemistry | Key specifications and capabilities | Target customer and application | Launch / latest capacity | Flagship status |
|---|---|---|---|---|---|
| Kyowanoic-N | Isononanoic acid (3,5,5-trimethylhexanoic acid) | Branched C9 acid. It is esterified with polyols to make polyol ester (POE) refrigeration oils that are compatible with HFC and low-GWP refrigerants such as R32 and R454B. | Refrigeration-oil formulators (Idemitsu Kosan is the largest disclosed customer) supplying air-conditioner compressor makers worldwide | Yokkaichi expansion in 2020 (about 1.5x); Chiba expansion completed July 2024 (about 1.5x, JPY 9.5 billion project) | Core flagship. The company claims world No.1 share in refrigeration-oil raw materials. [MTP5]; [ASR FY2025] |
| Octylic acid | 2-Ethylhexanoic acid (2-EHA) | Used as a co-acid in POE refrigeration oils. Also used to make the plasticizer (3G8) for PVB laminated-glass interlayers in automotive and architectural glass, and in metal soaps. | Refrigeration-oil makers; PVB film makers; coatings | Long-established; capacity included in the 2020 and 2024 expansions | Flagship |
| 1,3-Butylene glycol (1,3-BG) | Specialty diol | Humectant with high moisturizing power, low skin irritation and mild antibacterial action. The company has developed low-odor, high-purity grades by analyzing and suppressing trace impurities. | Cosmetics and skincare makers in Japan and Asia, including premium skincare | Ongoing quality upgrades; sales expansion through overseas distribution | The company claims No.3 globally in cosmetics raw materials. [Integrated Report 2025] |
| Diacetone acrylamide (DAAM) | Acrylamide monomer | Crosslinking monomer for water-based paints | Paint and coatings makers | — | Niche |
| Other specialty diols, acids and intermediates | Various | Used in lubricants, adhesives, pharmaceutical and agrochemical intermediates, and surfactants | Industrial and pharmaceutical customers | — | Niche |
Electronic Materials
| Product / brand | Chemistry | Key specifications and capabilities | Target customer and application | Launch / latest capacity | Flagship status |
|---|---|---|---|---|---|
| PMA-P | High-purity propylene glycol monomethyl ether acetate (PGMEA) | Ultra-low metal impurities (parts-per-trillion class). Quality is held consistent lot to lot using statistical process control. Primary photoresist casting solvent. | Photoresist makers and semiconductor fabs (logic, memory and advanced AI nodes); display makers | Quality-control building with an industry-leading cleanroom opened at Yokkaichi in 2022 | Flagship. The company claims world No.1 in high-purity solvents. [Integrated Report 2025] |
| PM-P | High-purity propylene glycol monomethyl ether (PGME) | Same quality regime as PMA-P. Used as a co-solvent and in thinner/edge-bead removal formulations. | Same customers as PMA-P | Same as PMA-P | Flagship |
| Kurokin Kasei advanced semiconductor materials | Contract-manufactured high-function organic materials | Specifics are confidential to customers. Research and production-engineering teams move products from lab to commercial production. | Semiconductor materials makers; electronics and medical customers | First unit autumn 2020; large unit autumn 2024 | Growth engine |
| EUV-related solvent development | PGMEA / PGME derivatives | Joint university research is validating the solvent's role in EUV lithography. | Leading-edge fabs | In development | Pipeline |
Basic Chemicals
| Product / brand | Chemistry | Applications | Notes |
|---|---|---|---|
| Octanol | 2-Ethylhexanol (2-EH) | Raw material for DOP plasticizer (wallpaper, flooring, automotive parts) and 2-ethylhexyl acrylate (paints, adhesives, pressure-sensitive adhesives, resins) | Core oxo alcohol |
| Oxocol 900 | Isononyl alcohol (INA) | Raw material for DINP plasticizer (wall and floor materials, automotive parts, wire coatings) | Feeds the J-Plus joint venture with Mitsubishi Chemical |
| Butanol | n-Butanol | Coatings solvent (automotive, building exteriors, cans); resin raw material | Commodity |
| Butyl acetate | n-Butyl acetate | Coatings and ink solvent | Commodity |
| Butyraldehyde and other aldehydes | Oxo intermediates | Mainly captive use | Platform intermediates |
The company claims domestic No.1 share in oxo alcohols. [Integrated Report 2025]
Other
| Business | Description |
|---|---|
| Kurokin Fines Co., Ltd. | Trading company (a subsidiary of Kurokin Kasei) selling health-food raw materials, pharmaceutical raw materials and industrial chemicals [ASR FY2025] |
Pipeline / new businesses (5th MTP "Strategy II: Laying the Groundwork for the Future")
| Program | Description | Stated milestone |
|---|---|---|
| Marine-biodegradable resin (PHB, polyhydroxybutyrate) | Produced by fermentation ("bio-manufacturing") from renewable feedstock | Build a mass-production system during the 5th MTP (by 2027) [MTP5] |
| Glycans for biopharmaceuticals | A library of more than 100 glycan types, with kg-scale mass-production technology established. Partner: GlyTech, Inc. (糖鎖工学研究所). | Commercialize during the 5th MTP period [ASR FY2025] |
| Next-generation optical lens materials (alicyclic compounds / monomers) | Oxo-derived monomers that offer heat resistance, low dielectric properties and low water absorption, for automotive (ADAS), smartphone and 5G/6G camera lenses | Pilot production and paid samples underway; commercial plant "as early as 2027" [MTP5] |
| Biostimulants | Co-development with Accplanta Inc. to improve crop tolerance of climate stress | Field trials [ASR FY2025] |
| CO2 utilization | CO2 captured at Chiba (unit commissioned February 2025) and Yokkaichi is reused as oxo-gas feedstock | Operating [ASR FY2025] |
Financial Narrative
Income statement
Sources: [ASR FY2025] five-year summary, P&L and dividend data; Envalith/EDINET DB for gross profit, SG&A and EBITDA.
EBITDA here follows the company's definition: operating income plus depreciation plus goodwill amortization. Diluted EPS equals basic EPS because no potentially dilutive shares exist. [ASR FY2025]
Margins (%, derived)
Revenue CAGR, FY2021–FY2025: -0.4% per year (derived). Measured from the COVID-depressed FY2020 base of about JPY 77.3 billion, the five-year average growth was 8.3% [MKT]. The three-year average growth rate is 0.1%.
Balance sheet
Source: [ASR FY2025]; [TAN FY24]. FY2021–FY2022 shareholders' equity is derived as equity ratio multiplied by total assets.
Debt and working-capital detail (FY2023–FY2025, JPY million)
Source: [ASR FY2025]; [ASR FY2024].
Company material from 2018–2022 indicates net debt was on a declining trend through 2021.
Cash flow: notes and sources
Source: [ASR FY2025]. FCF is derived.
Source: [ASR FY2025]; [ASR FY2024].
Ratios (derived unless stated)
Sources: [ASR FY2025]; Envalith for ROA.
ROIC is per the company's KPI table [ASR FY2025]. EDINET DB computes a pre-tax ROIC of 13.4% for FY2025, a methodological difference.
Commentary on trends, inflections and drivers
FY2021 was a cyclical peak, not the base. Operating income nearly tripled to JPY 19.7 billion. The company attributes the gain to two factors:
-
JPY 8.9 billion from wider price spreads, as Asian oxo markets were tight because of competitor outages and naphtha was rising (which created inventory gains).
-
JPY 7.2 billion from volume and mix [MTP4 / FY2021 results deck].
ROE of 27.9% reflected this exceptional environment. FY2022 to FY2023 saw spread normalization. Gross margin fell 8.5 percentage points over two years, and operating income bottomed at JPY 9.9 billion in FY2023.
FY2024 was the specialty-led recovery. Operating income rose 22.6% to JPY 12.2 billion. Functional Materials operating income rose 31% on air-conditioner demand, particularly in India and other emerging markets, plus cost pass-through. Electronic Materials operating income rose 28% on AI-related demand. Cash conversion, however, was weak. OCF of JPY 7.0 billion was hit by a JPY 4.6 billion increase in receivables. Capex of JPY 8.4 billion (cash basis) for the Chiba expansion produced negative FCF.
FY2025 was a disappointment against plan. The original guidance of sales JPY 127.4 billion and operating income JPY 14.0 billion was missed by a wide margin. Actual sales were JPY 115.1 billion and operating income JPY 11.2 billion, 20% below guidance. Through the first nine months, operating income had been up 16% year on year. The shortfall therefore came almost entirely in Q4 2025: derived Q4 operating income was about JPY 2.7 billion. The company cited three causes:
-
An air-conditioner inventory correction in the second half, from US pre-buying ahead of the refrigerant change and fading Chinese subsidies.
-
Unseasonable weather in emerging markets.
-
A one-off raw-material procurement problem in Basic Chemicals [ASR FY2025, Issues to Address].
Higher depreciation from the Chiba plant (JPY 6.2 billion versus JPY 4.8 billion) also weighed. Cash generation was strong, though. OCF doubled to JPY 13.8 billion on receivable collection, funding JPY 8.6 billion of shareholder returns.
Balance sheet. The equity ratio rose from 45.0% to 53.6% over four years even as the company returned capital. Net debt of about JPY 10 billion is about 0.6 times EBITDA. The working-capital cycle lengthened in FY2025 to 111 days as inventory rose JPY 3.6 billion ahead of planned turnarounds and during the air-conditioner correction. This is a monitorable for FY2026.
FY2026 year to date: inflection. First-half operating income was JPY 7.5 billion, up 25% year on year, with a margin of 14.1%. This was the best first half since FY2021. The quarterly progression matters:
-
Q1 FY2026 operating income was JPY 2.1 billion, down 22.6%.
-
Q2 standalone operating income was about JPY 5.4 billion (derived). That is up about 64% year on year and is the strongest quarter since 2021.
Electronic Materials, up 51%, and a Basic Chemicals price-led recovery drove the result. Functional Materials remains in correction.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Field Details
| Business field | What it contains | Key products | Production sites |
|---|---|---|---|
Functional Materials | Refrigeration-oil raw materials; cosmetics raw materials; other specialty acids and diols | Kyowanoic-N (isononanoic acid), octylic acid (2-EHA), 1,3-butylene glycol; diacetone acrylamide | Yokkaichi, Chiba |
Electronic Materials | High-purity solvents for photoresists and displays; advanced semiconductor materials made by contract at Kurokin Kasei | PM-P (PGME), PMA-P (PGMEA); Kurokin Kasei next-generation semiconductor materials | Yokkaichi (including the 2022 quality-control building); Kurokin Kasei (Chiryu and Minokamo) |
Basic Chemicals | Solvents, plasticizer raw materials, resin raw materials | n-Butanol, octanol (2-ethylhexanol), Oxocol 900 (isononyl alcohol), butyl acetate | Yokkaichi, Chiba |
Other | Trading and miscellaneous, mainly Kurokin Fines (health-food and pharma ingredients) | — | — |
Revenue by Segment
| Business field | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Functional Materials sales (JPY Mn) | 50,374 | 55,874 | 56,686 |
Electronic Materials sales (JPY Mn) | 11,668 | 11,961 | 12,309 |
Basic Chemicals sales (JPY Mn) | 52,352 | 51,189 | 45,374 |
Other sales (JPY Mn) | 822 | 733 | 727 |
Total net sales (JPY Mn) | 115,217 | 119,758 | 115,098 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment — Functional Materials OI
| Business field | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Functional Materials OI (JPY Mn) | 8,430 | 11,063 | 10,931 |
Electronic Materials OI (JPY Mn) | 1,883 | 2,407 | 2,681 |
Basic Chemicals OI (JPY Mn) | 2,611 | 1,970 | 916 |
Other OI (JPY Mn) | 167 | 62 | 129 |
Corporate costs (JPY Mn) | -3,146 | -3,308 | -3,410 |
Consolidated operating income (JPY Mn) | 9,946 | 12,195 | 11,248 |
Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Functional Materials OI margin (%) | 16.7 | 19.8 | 19.3 |
Electronic Materials OI margin (%) | 16.1 | 20.1 | 21.8 |
Basic Chemicals OI margin (%) | 5.0 | 3.8 | 2.0 |
Functional Materials sales YoY (%) | — | 10.9 | 1.5 |
Electronic Materials sales YoY (%) | — | 2.5 | 2.9 |
Basic Chemicals sales YoY (%) | — | -2.2 | -11.4 |
Functional Materials % of total sales | 43.7 | 46.7 | 49.3 |
Electronic Materials % of total sales | 10.1 | 10.0 | 10.7 |
Basic Chemicals % of total sales | 45.4 | 42.7 | 39.4 |
Segment Revenue
| Business field | Q1 FY2026 sales | Q1 YoY (%) | Q1 FY2026 OI | Q1 OI YoY (%) | 1H FY2026 sales | 1H YoY (%) | 1H FY2026 OI | 1H OI YoY (%) |
|---|---|---|---|---|---|---|---|---|
Functional Materials | 12,109 | -17.6 | 2,156 | -16.1 | 24,850 | -15.1 | — | -10.4 |
Electronic Materials | 3,365 | +22.5 | 754 | +33.0 | 7,360 | +26.3 | 1,817 | +51.3 |
Basic Chemicals | 9,942 | -11.0 | 191 | -58.2 | — | -10.9 | 2,296 | +270.5 |
Consolidated | 25,581 | -11.2 | 2,094 | -22.6 | 53,299 | -9.3 | 7,501 | +24.9 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 117,110 | 114,880 | 115,217 | 119,758 | 115,098 |
Cost of sales (JPY Mn) | 84,876 | 90,434 | 93,279 | 94,504 | 90,232 |
Gross profit (JPY Mn) | 32,233 | 24,445 | 21,937 | 25,253 | 24,866 |
SG&A (JPY Mn) | 12,547 | 11,989 | 11,991 | 13,057 | 13,618 |
Operating income (JPY Mn) | 19,685 | 12,456 | 9,946 | 12,195 | 11,248 |
EBITDA, company definition (JPY Mn) | 24,188 | 16,749 | 14,597 | 17,168 | 17,581 |
Ordinary income (JPY Mn) | 19,809 | 12,709 | 9,725 | 12,055 | 10,793 |
Pre-tax income (JPY Mn) | 19,788 | 11,634 | 9,725 | 11,918 | 10,793 |
Income taxes (JPY Mn) | 5,924 | 3,382 | 2,795 | 3,447 | 2,839 |
Net income attributable to owners (JPY Mn) | 13,691 | 8,073 | 6,826 | 8,360 | 7,799 |
EPS basic (JPY) | 368.95 | 217.73 | 184.23 | 225.81 | 218.15 |
EPS diluted (JPY) | 368.95 | 217.73 | 184.23 | 225.81 | 218.15 |
Dividends per share (JPY) | 75 | 85 | 90 | 90 | 105 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 27.5 | 21.3 | 19.0 | 21.1 | 21.6 |
Operating margin (%) | 16.8 | 10.8 | 8.6 | 10.2 | 9.8 |
EBITDA margin (%) | 20.7 | 14.6 | 12.7 | 14.3 | 15.3 |
Net margin (%) | 11.7 | 7.0 | 5.9 | 7.0 | 6.8 |
Effective tax rate (%) | 29.9 | 29.1 | 28.7 | 28.9 | 26.3 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (JPY Mn) | 122,069 | 131,247 | 124,498 | 131,462 | 130,101 |
Cash and equivalents (JPY Mn) | 16,934 | 10,926 | 9,684 | 7,158 | 6,719 |
Net assets (JPY Mn) | 57,505 | 62,066 | 66,493 | 71,919 | 72,629 |
Shareholders' equity (JPY Mn) | 54,919 | 59,350 | 63,744 | 69,088 | 69,676 |
Equity ratio (%) | 44.99 | 45.22 | 51.20 | 52.55 | 53.56 |
Book value per share (JPY) | 1,480.27 | 1,601.26 | 1,720.81 | 1,866.63 | 1,990.25 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Interest-bearing debt excluding leases (JPY Mn) | 14,820 | 17,747 | 16,949 |
of which short-term borrowings (JPY Mn) | — | 9,750 | 9,950 |
of which commercial paper (JPY Mn) | 0 | 2,996 | 1,999 |
of which bonds, long-term (JPY Mn) | — | 5,000 | 5,000 |
Lease obligations (JPY Mn) | — | 1,458 | 1,341 |
Net interest-bearing debt excluding leases (JPY Mn) | 5,135 | 10,588 | 10,230 |
Goodwill (JPY Mn) | — | 840 | 705 |
Other intangibles (JPY Mn) | — | 506 | 448 |
Current assets (JPY Mn) | — | 69,366 | 67,253 |
Current liabilities (JPY Mn) | — | 46,649 | 45,231 |
Working capital (JPY Mn) | — | 22,717 | 22,022 |
Inventories (JPY Mn) | — | 20,712 | 24,270 |
Trade receivables (JPY Mn) | — | 37,337 | 32,877 |
Trade payables (JPY Mn) | — | 24,408 | 22,398 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | 17,402 | 5,131 | 13,201 | 6,982 | 13,783 |
Investing cash flow (JPY Mn) | -4,395 | -10,082 | -4,937 | -8,897 | -4,627 |
Financing cash flow (JPY Mn) | -5,168 | -1,076 | -9,501 | -645 | -9,566 |
FCF proxy, OCF plus investing CF (JPY Mn) | 13,007 | -4,951 | 8,264 | -1,915 | 9,156 |
Dividends & Capital Returns
| Metric | FY2024 | FY2025 |
|---|---|---|
Purchase of PP&E, cash basis (JPY Mn) | 8,432 | 4,653 |
Capital expenditure, accrual basis (JPY Mn) | 6,603 | 4,231 |
Depreciation (JPY Mn) | 4,839 | 6,199 |
Goodwill amortization (JPY Mn) | 134 | 134 |
Dividends paid (JPY Mn) | 3,342 | 3,540 |
Share repurchases, including Board Benefit Trust (JPY Mn) | 69 | 5,054 |
Total shareholder returns (JPY Mn) | 3,411 | 8,594 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, company-reported (%) | 27.86 | 14.13 | 11.09 | 12.59 | 11.24 |
ROA, net income / average assets (%) | 11.2 | 6.2 | 5.5 | 6.4 | 6.0 |
Asset turnover (x) | — | 0.91 | 0.90 | 0.94 | 0.88 |
Dividend payout, parent-only, company-reported (%) | 21.10 | 40.87 | 48.03 | 41.41 | 49.02 |
Returns & Leverage Ratios (%) and Financial Ratios (x) (FY2023–FY2025)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROIC, company KPI basis (%) | — | 10 | 10 |
Current ratio (x) | — | 1.49 | 1.49 |
Debt / equity (x) | 0.23 | 0.26 | 0.24 |
Net debt / EBITDA (x) | 0.35 | 0.62 | 0.58 |
Interest coverage, OI / interest expense (x) | — | 121 | 57 |
Days sales outstanding (days) | — | 114 | 104 |
Days inventory outstanding (days) | — | 80 | 98 |
Days payables outstanding (days) | — | 94 | 91 |
Cash conversion cycle (days) | — | 100 | 111 |
Revenue by Region
| Region | FY2024 | FY2025 |
|---|---|---|
Japan (JPY Mn) | 90,541 | 87,503 |
China (JPY Mn) | 15,531 | 12,937 |
Other Asia (JPY Mn) | 8,139 | 7,800 |
Other regions (JPY Mn) | 5,545 | 6,856 |
Total (JPY Mn) | 119,758 | 115,098 |
Geographic Revenue
| Region | FY2025 YoY growth (%) | FY2024 share (%) | FY2025 share (%) |
|---|---|---|---|
Japan | -3.4 | 75.6 | 76.0 |
China | -16.7 | 13.0 | 11.2 |
Other Asia | -4.2 | 6.8 | 6.8 |
Other regions | +23.6 | 4.6 | 6.0 |
Per-Share Data and Capital Markets Data (JPY)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price, derived from PER times EPS (JPY) | 3,180 | 2,693 | 2,270 | 2,037 | 2,476 |
Annual high (JPY) | 3,540 | 3,280 | 2,803 | 2,476 | 3,050 |
Annual low (JPY) | 2,322 | 2,335 | 2,140 | 1,769 | 1,945 |
Total shareholder return, five-year cumulative index (%) | 119.2 | 104.5 | 92.2 | 87.0 | 107.0 |
TOPIX including dividends, comparison index (%) | 112.7 | 110.0 | 141.1 | 169.9 | 213.2 |
Change by Period
| Period | Change |
|---|---|
Year to date (versus about JPY 2,476 at end-2025) | about +36% |
Approximately 1 year (versus the 52-week low of JPY 2,315 on 21 November 2025) | +45% from the low |
Approximately 3 years (versus about JPY 2,270 at end-2023) | about +48% |
Approximately 5 years (versus about JPY 3,180 at end-2021) | about +6% |
Valuation Multiples
| Multiple | KH Neochem | Basis |
|---|---|---|
P/E on company forecast | 13.5x | Company EPS forecast of JPY 248.5 [MKT] |
P/E on consensus | about 11.8x | Consensus FY2026 EPS of JPY 285.6 [MKT] (derived) |
P/B | 1.58x | Actual book value [MKT] |
EV/EBITDA | about 7.8x | EV of about JPY 138 billion (market cap 124.8 + net debt 10.2 + non-controlling interests 3.0) divided by FY2025 EBITDA of 17.6 (derived) |
EV/Sales | about 1.2x | Derived |
Dividend yield | 3.87% | FY2026 DPS of JPY 130 |
Market capitalization | JPY 124.8 billion | [MKT] |
Valuation Snapshot
| Metric | Value |
|---|---|
FY2026 consensus ordinary income | JPY 14.2 billion, versus company guidance of JPY 12.6 billion |
FY2026 consensus EPS | JPY 285.6 |
FY2027 consensus EPS | JPY 317.0 |
12-month-forward consensus EPS | JPY 309.1 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Annual DPS (JPY) | 75 | 85 | 90 | 90 | 105 |
Interim DPS (JPY) | 30 | 42.5 | 45 | 45 | 52.5 |
Consolidated payout (%) | 20.3 | 39.0 | 48.9 | 39.9 | 48.1 |
Capital Instruments
| Instrument | Within 1 year | 1–2 years | 2–3 years | 3–4 years | 4–5 years | Over 5 years |
|---|---|---|---|---|---|---|
Short-term borrowings | 9,950 | — | — | — | — | — |
Commercial paper | 1,999 | — | — | — | — | — |
Bonds (issued 2024) | — | — | — | 5,000 | — | — |
Lease obligations | 118 | 108 | 105 | 108 | 110 | 788 |
Analyst Conclusions
Management guidance (FY2026, unchanged since 6 February 2026)
| Metric | FY2025 actual | FY2026 guidance | YoY (%) | 1H FY2026 actual | 1H share of full year (%) |
|---|---|---|---|---|---|
| Net sales (JPY M) | 115,098 | 114,000 | -1.0 | 53,299 | 46.8 |
| Operating income (JPY M) | 11,248 | 13,500 | +20.0 | 7,501 | 55.6 |
| Ordinary income (JPY M) | 10,793 | 12,600 | +16.7 | 7,448 | 59.1 |
| Net income (JPY M) | 7,799 | 8,700 | +11.5 | 5,282 | 60.7 |
| EPS (JPY) | 218.15 | 248.45 | — | 150.85 | — |
| DPS (JPY) | 105 | 130 | +23.8 | 55 | — |
Source: [TAN FY25]; [TAN 1H26]; [DIV 0804].
Management's stated assumptions for FY2026 are domestic naphtha at JPY 60,000 per kilolitre and an exchange rate of USD 1 = JPY 150. The implied second-half operating income is JPY 6.0 billion, below the first half's JPY 7.5 billion. Management kept guidance because of Middle East uncertainty. This sets up a conservative bar: consensus ordinary income of JPY 14.2 billion is 13% above guidance.
Bull case
-
Electronic Materials compounding. Operating income grew 51% in first-half FY2026. If full-year FY2026 operating income reaches about JPY 3.5–3.8 billion and the 2024 Kurokin capacity fills alongside EUV growth (46 to 205 thousand gallons over 2024–2029), this field alone could add JPY 1–2 billion of operating income by FY2027.
-
Functional Materials normalization. The air-conditioner correction is cyclical, not structural (140 to 190 million units by 2030). With new Chiba capacity and higher depreciation already absorbed, a volume recovery from 2027 could push this field's operating income back above its FY2024 peak of JPY 11.1 billion.
-
Capital-return re-rating plus an activist floor. A 50% payout and DOE of at least 5% imply DPS of about JPY 100 even in a downturn (5% DOE on about JPY 2,000 book value per share). With Strategic Capital at 18%, further measures are plausible: cross-shareholding sales (JPY 7.2 billion), buybacks from the JPY 13.5 billion strategic window, or Basic Chemicals restructuring. At about 7.8x EV/EBITDA and a P/B of 1.58x, a move toward the consensus target of JPY 3,850 or higher is credible.
Bear case
-
Functional Materials is ex-growth for longer. First-half FY2026 sales fell 15%. US refrigerant transitions, the Chinese property market and air-conditioner saturation in China could keep volumes flat through 2027. Customer concentration (Idemitsu at 17.5%) limits pricing power.
-
First-half Basic Chemicals profit is not repeatable. Operating income of JPY 2.3 billion (up 270%) appears to be driven by price increases outrunning average-cost inventory during a raw-material spike. A reversal in the second half or in FY2027, plus continued Chinese imports, could take Basic Chemicals back to about JPY 1 billion or below.
-
Execution and credibility. The FY2025 guidance was missed by 20%. The MTP cumulative operating income target of JPY 44.9 billion requires about JPY 20 billion in FY2027, which is implausible. VISION 2030's JPY 25 billion operating income target looks out of reach, and R&D at about 1% of sales may be too thin to deliver new businesses (PHB, glycans, optical monomers) at a meaningful scale.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst |
|---|---|
| Early November 2026 | Q3 FY2026 results. Watch for a guidance revision (consensus is above guidance) and whether Functional Materials volumes have bottomed. |
| From November 2026 onward | Strategic Capital's next moves. Watch for shareholder proposals ahead of the March 2027 AGM (Japanese submission deadlines are typically about 8 weeks before the AGM). |
| Early February 2027 | FY2026 results and FY2027 guidance. Watch for possible MTP target revisions, new buyback authorizations and the year-end DPS of JPY 75. |
| Ongoing | Basic Chemicals structural reform. Any capacity closure, partnership or Japanese oxo consolidation announcement. |
| Ongoing | Raw-material and FX path. Naphtha relative to the JPY 60,000 per kilolitre assumption, the Middle East situation, and JPY/USD relative to 150. |
| Ongoing | Working capital. Whether inventory (JPY 24.3 billion at end-FY2025) normalizes after turnarounds. |
| 2,027 | New-business milestones. PHB mass-production decision; alicyclic monomer facility investment decision. |
| March 2027 AGM | Vote outcomes and any further board changes |
Analyst verdict
KH Neochem is a high-quality niche franchise attached to a structurally challenged commodity business, and its equity story has shifted from growth to capital efficiency.
The franchise is genuine. The company dominates refrigeration-oil raw materials and is a premium supplier of photoresist-grade solvents. Over FY2023 to FY2025 these two fields earned business-field margins of about 16–22% and generated over 90% of segment profit.
The company has nonetheless failed to grow. FY2025 sales of JPY 115.1 billion sit below FY2021's level. Operating income of JPY 11.2 billion is 43% below the FY2021 peak. Management missed its own FY2025 operating income guidance by 20%. The cumulative 5th MTP target now looks out of reach without an exceptional FY2027.
Two developments in 2026 change the debate. First, results inflected: second-quarter operating income of about JPY 5.4 billion was the strongest quarter since 2021, driven by AI-linked Electronic Materials and agile pricing. Second, the ownership register changed: Strategic Capital accumulated an 18.24% stake within four months. The board's response so far has been shareholder-friendly. A former Mizuho Securities M&A banker was added as a director, and the dividend policy was raised to a 50% payout with a DOE floor of at least 5%. The FY2026 dividend of JPY 130 is 24% higher year on year.
At about 13.5x company-guided EPS, about 7.8x EV/EBITDA, a 3.9% yield and a strong balance sheet (net debt about 0.6x EBITDA), the stock is reasonably priced for a business whose specialty core should resume growth in 2027. The real swing factors are Basic Chemicals and the activist dynamic. A credible Basic Chemicals restructuring, a buyback funded from the JPY 13.5 billion strategic window, and reduction of the JPY 7.2 billion cross-shareholding book would each lift ROE toward the 15% target without heroic operating assumptions.
Downside risks are concentrated in a prolonged air-conditioner correction and a reversal of first-half Basic Chemicals inventory gains. Net, the risk-reward is moderately favorable. The investment case rests on visible capital-return support, conservative FY2026 guidance and governance-driven optionality rather than on top-line growth, which management has yet to deliver.
The key near-term proof points are Q3 FY2026 results in early November 2026 and any activist proposals ahead of the March 2027 AGM.
Market-share rankings are company self-reported. Items labeled "analyst inference" are interpretive and not stated in company filings.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Born (age in Oct 2026) | Tenure | Background and prior roles |
|---|---|---|---|---|
Michio Takahashi (髙橋理夫) | Representative Director, President & CEO, Chair of the Board | Feb 1965 (61) | Director since 2013; President since March 2019 | Joined Kyowa Hakko Kogyo in 1987. Basic Chemicals division head (2011). Managing Director (2016); Executive Vice President (2017). Holds 39,619 shares including 30,619 Board Benefit Trust points. |
Toshiaki Toma (藤間敏明) | Director, Senior Managing Executive Officer, Corporate Planning; Chief Strategy Officer (CSO) and Chair of the Sustainability Committee | Jul 1974 (52) | Director since March 2025 | Joined Kyowa Hakko Kogyo in 1998. Postings in the US with Kyowa Hakko USA and Chemical Americas (EVP). Corporate Planning head from 2023. |
Taro Hasuo (蓮尾太郎) | Director, Managing Executive Officer (appears to have succeeded to the CFO/IR contact role) | Jan 1969 (57) | Director since March 2026; joined January 2026 | Joined Industrial Bank of Japan (now Mizuho) in 1992. Head of M&A Advisory at Mizuho Securities USA (2015). Executive Officer and Head of the Resources & Materials Industry Group, Mizuho Securities Global Investment Banking (2023–2025). |
Sayoko Miyairi (宮入小夜子) | Outside Director (independent); Nomination & Compensation Committee member | Nov 1956 (69) | Since 2019 | Partner at Scholar Consulting. Professor Emerita at Kaichi International University. Outside director at Toyo Engineering and Nippon Seikan. |
Atsushi Tsuchiya (土屋淳) | Outside Director (independent); Nomination & Compensation Committee member | Oct 1952 (73) | Since 2020 | Researcher at Argonne and Lawrence Berkeley national laboratories. Worked at Mitsubishi Kasei, where he was President of Verbatim. Director at Rohm and Haas Japan. President of Heraeus Japan (2007–2018). |
Yuji Kikuchi (菊池祐司) | Outside Director (independent); Chair of the Nomination & Compensation Committee | Feb 1964 (62) | Since 2020 | Attorney and partner at Tokyo Hatchobori Law Office. Former official at the Securities and Exchange Surveillance Commission. Outside director at Tachibana Securities (2026). |
Isao Takahashi (高橋功) | Director, full-time Audit & Supervisory Committee member and committee chair | Aug 1964 (62) | Since March 2024 | Formerly at Fujisawa / Astellas. Joined the company in 2017. Managing Executive Officer and head of Corporate Administration. |
Keiko Tamura (田村恵子) | Outside Director (independent), Audit & Supervisory Committee member | Aug 1963 (63) | Statutory auditor from 2020; director from 2024 | Partner at Asahi Law Offices. Outside director at Amano Corp. Outside auditor at Norinchukin Trust. |
Yoji Murohashi (室橋陽二) | Outside Director (independent), Audit & Supervisory Committee member | Feb 1965 (61) | Since March 2026 | CPA. Former Senior Partner at EY ShinNihon (until 2023). |
Directors' Remuneration
| Category | Total pay | Fixed cash | Performance-linked cash | Performance-linked stock (Board Benefit Trust) | Number of persons |
|---|---|---|---|---|---|
Executive directors (excluding Audit Committee and outside directors) | 142 | 76 | 31 | 34 | 4 |
Internal Audit & Supervisory Committee director | 21 | 21 | 0 | 0 | 1 |
Outside directors | 54 | 54 | 0 | 0 | 5 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Mar 2024 | Directors Toshihiro Matsuoka and Yukihiro Isogai retire. Isao Takahashi becomes a full-time Audit Committee director. | Conversion to the Audit & Supervisory Committee structure |
Mar 2025 | Director Tatsuo Shintani retires; Toshiaki Toma joins the board. | Generational renewal; Toma is the strategy lead |
Jan 2026 | Taro Hasuo joins from Mizuho Securities. | Analyst inference: this brings in M&A and capital-markets expertise as activist ownership builds. |
26 Mar 2026 | CFO Shinya Hamamoto (a former Industrial Bank of Japan banker, director since 2020) leaves the board. Outside director Kazuhiro Kawai leaves the board. Hasuo and Murohashi are elected. Toma is promoted to Senior Managing Executive Officer. | AGM |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | The Master Trust Bank of Japan (trust account) | 5,206,300 | 14.81 |
| 2 | Custody Bank of Japan (trust account) | 2,827,400 | 8.04 |
| 3 | Tosoh Corporation | 1,852,000 | 5.27 |
| 4 | State Street Bank & Trust 505001 | 1,193,279 | 3.39 |
| 5 | Mizuho Bank | 733,300 | 2.09 |
| 6 | Government of Norway | 655,929 | 1.87 |
| 7 | Juniper (Riyadh) | 655,200 | 1.86 |
| 8 | BNY 133652 | 645,800 | 1.84 |
| 9 | State Street Bank & Trust 505019 | 521,461 | 1.48 |
| 10 | Northern Trust (Wales Pension Partnership) | 517,400 | 1.47 |
Major Shareholders by Holder
| Holder | % |
|---|---|
Intertrust Trustees (Cayman) as trustee of JAPAN-UP. Analyst inference: this is consistent with the fund vehicle advised by Strategic Capital. | 18.14 |
The Master Trust Bank of Japan (trust account) | 12.60 |
Custody Bank of Japan (trust account) | 8.02 |
Tosoh Corporation | 5.27 |
Major Shareholders by Filer
| Filer | Reported stake (%) | Obligation date | Notes |
|---|---|---|---|
Strategic Capital Inc. (activist; Representative Director Tsuyoshi Maruki) | 18.24 | 17 Jun 2026 | Holding rose from 13.13% (9 Mar 2026) to 14.35% (10 Mar), 15.36% (31 Mar), 16.08% (12 May), 17.08% (1 Jun), 17.59% (9 Jun) and 18.24% (17 Jun), equal to 6,774,700 shares. |
Amova Asset Management (formerly Nikko AM), within the Sumitomo Mitsui Trust group | 7.68 | 29 Dec 2025 | Group total about 10.2% including Sumitomo Mitsui Trust Bank (0.49%) and SuMi Trust AM (2.01%). The bank's stake decreased in March 2026. |
Trivista Capital | 6.07 | 31 May 2023 | Current holding not confirmed |
Wellington Management group | 3.98 + 2.98 + 0.59 | 15 Aug 2025 | Decrease reported in March 2026 |
Nomura Asset Management / Nomura International | 3.72 + 0.23 | 15 Sep 2025 | — |
Mizuho Bank / Mizuho Trust / Asset Management One | 1.97 + 0.40 + 1.94 | 14 Nov 2025 | — |
Competitive Landscape
Competitor Detail
| Field / product | Competitor | Country | Relative positioning |
|---|---|---|---|
Refrigeration-oil raw materials (isononanoic acid, 2-EHA) | OQ Chemicals (formerly Oxea) | Germany / Oman | Major global producer of isononanoic acid and 2-EHA. |
Same | BASF | Germany | Large oxo and 2-EHA producer; broad portfolio |
Same | Eastman Chemical | USA | 2-EHA and oxo derivatives |
Same | Perstorp (Petronas Chemicals) | Sweden / Malaysia | 2-EHA and polyols (POE co-raw materials) |
High-purity PGME / PGMEA | Dow | USA | Global glycol-ether leader |
Same | Daicel | Japan | Domestic electronic-solvent competitor |
Same | Shiny Chemical Industrial; Chang Chun Group | Taiwan | Large Asian PGMEA suppliers close to TSMC |
Cosmetic 1,3-BG | Daicel | Japan | Major 1,3-BG producer; key domestic rival |
Same | OQ Chemicals | Germany / Oman | Global 1,3-BG producer |
Oxo alcohols (2-EH, butanol, INA) | Mitsubishi Chemical Group | Japan | Domestic oxo peer and joint-venture partner |
Same | Chinese producers (e.g., Wanhua, Sinopec affiliates, Shandong producers) | China | Large new capacity driving imports into Japan [MTP5] |
Same | LG Chem; Hanwha Solutions | Korea | Regional oxo producers |
Peer Comparison FY2025
| Metric | KH Neochem (FY Dec-2025) | Daicel (FY Mar-2026) | Mitsubishi Chemical Group (latest FY) | Asahi Kasei (latest FY) |
|---|---|---|---|---|
Revenue (JPY Bn) | 115.1 | 579.6 | 3,700 | 3,070 |
Revenue growth (%) | -3.9 | -1.2 | — | — |
Operating margin (%) | 9.8 | 7.3 | 0.8 | 7.5 |
ROE (%) | 11.2 | — | 0.7 | 8.0 |
Equity ratio (%) | 53.6 | 42.6 | 30.0 | 50.5 |
R&D / sales (%) | 1.2 | — | — | — |
Dividend yield (%) | 3.9 | — | — | 2.8 |
“—” = not publicly disclosed.



